

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



VOLUNTARY ANNOUNCEMENT

NATIONAL EXCLUSIVE PRODUCTS OF THE GROUP – METHYLPHENIDATE HYDROCHLORIDE TABLETS AND CHLOROTRIANISENE PILLS ARE EXPECTED TO BE PUT INTO PRODUCTION BY 2017 FURTHER EXPANDING PRODUCT PORTFOLIO

This announcement is made by China NT Pharma Group Company Limited (the “**Company**”) and its subsidiaries (collectively, the “**Group**”) on a voluntary basis.

The Company is pleased to announce that, Suzhou First Pharmaceutical Co., Ltd., the wholly-owned subsidiary of the Group, will establish Suzhou First Pharmaceutical Taizhou Co., Ltd.* (蘇州第壹製藥泰州有限公司) and its sub-plant in Chinese Medicine City, Taizhou, Jiangsu Province, for the production of its core products, Methylphenidate Hydrochloride Tablets and Chlorotrianisene Pills. Both of these two products are exclusively owned by the Group and have already obtained the production approval documents issued by the State Food and Drug Administration of China.

Methylphenidate Hydrochloride Tablets are used for the treatment of attention deficit hyperactivity disorder (hyperkinetic syndrome of childhood, minimal brain dysfunction), narcolepsy, and coma caused by the overdosage of central depressants like Barbiturate and Chloral Hydrate. The raw materials of Methylphenidate Hydrochloride Tablets are exclusive nationwide and such pharmaceutical products are under government’s centralized procurement and management. The launching of such products can further enhance the Company’s development in the therapeutic area of central nervous system.

Chlorotrianisene Pills are used for the treatment of women menopause syndrome, symptoms caused by estrogen deficiency after surgery, dysfunctional uterine bleeding in adolescent puberty, estrogen replacement therapy for female hypogonadotropic hypogonadism and male prostate hyperplasia. Both the raw materials and medical preparations (pills) of Chlorotrianisene Pills are exclusive nationwide.

The production lines of Suzhou First Pharmaceutical Taizhou Co., Ltd. are expected to be completed by 2017, with the above two principal products expected to be put into market by the end of 2017 or earlier. The products will provide better treatment choices for physicians and patients and thus have positive market prospects. The Group will continuously enhance its research and development capabilities, further bolster its diversified product portfolio and drive its sustainable growth.

Further announcement(s) will be made by the Company in relation to the progress of the above mentioned pharmaceutical products as and when appropriate. Shareholders and public investors are reminded to exercise caution when dealing in the shares of the Company.

By order of the Board
China NT Pharma Group Company Limited
Ng Tit
Chairman

Hong Kong, 1 December 2015

As at the date of this announcement, the executive directors of the Company are Mr. Ng Tit, Ms. Chin Yu and Mr. Wu Weizhong; the non-executive director of the Company is Dr. Qian Wei; and the independent non-executive directors of the Company are Mr. Yue Nien Martin Tang, Mr. Patrick Sun and Dr. Lap-Chee Tsui.

* For identification purpose only